By Counterforce Health Team in Daybue (trofinetide) —

How to Get Daybue (trofinetide) Covered by Aetna (CVS Health) in Washington: Complete PA Guide, Forms, and Appeal Process

Answer Box: Aetna (CVS Health) requires prior authorization for Daybue (trofinetide) with genetic confirmation of Rett syndrome (MECP2 mutation), specialist prescription, and age ≥2 years. Submit PA through Aetna provider portal with MECP2 test results, neurologist notes, and weight-based dosing calculation. If denied, Washington offers external review through Independent Review Organizations with 180-day appeal window. Start today: contact prescribing neurologist to gather genetic test results and clinical documentation.

Table of Contents

ICD-10 and Diagnostic Coding Requirements

The primary diagnosis code for Rett syndrome is F84.2, classified under Mental, Behavioral and Neurodevelopmental Disorders. This code must be supported by comprehensive documentation that meets both clinical and genetic criteria.

Required Documentation Elements

Clinical manifestations that support F84.2 coding:

  • Partial or complete loss of acquired purposeful hand skills
  • Partial or complete loss of acquired spoken language
  • Gait abnormalities (ataxia, apraxia)
  • Stereotypic hand movements (wringing, clapping, tapping)
  • Evidence of regression in development

Genetic confirmation requirement: Aetna CVS Health requires documented pathogenic variant in the MECP2 gene located on the X chromosome. The genetic test results must show a confirmed mutation—clinical diagnosis alone is insufficient for coverage approval.

Clinician Corner: When documenting for F84.2, include baseline severity assessments using validated tools like the Rett Syndrome Behavior Questionnaire (RSBQ) or Clinical Global Impression-Improvement (CGI-I) scale. These provide measurable outcomes for reauthorization requests.

Product Coding: HCPCS, NDC, and Billing Units

HCPCS and NDC Codes

Primary codes for Daybue:

  • HCPCS: J8499 (Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified)
  • NDC: 63090-660-01 (10-digit) or 63090-0660-01 (11-digit)
  • Concentration: 200 mg/mL oral solution in 450 mL bottles

Dosing and Units Conversion

Daybue dosing is weight-based, administered twice daily (morning and evening):

Patient Weight (kg) Dose (mg BID) Volume (mL BID) Monthly Volume (mL)
9 to <12 5,000 25 1,500
12 to <20 6,000 30 1,800
20 to <35 8,000 40 2,400
35 to <50 10,000 50 3,000
≥50 12,000 60 3,600

Enteral administration: Daybue can be administered via gastrostomy tube (G-tube) without dilution. Use modifier -JD for enteral route when billing for G-tube administration.

Aetna CVS Health Prior Authorization Process

Coverage Requirements

Aetna CVS Health covers Daybue when all criteria are met:

Clinical criteria:

  • Patient age ≥2 years
  • Confirmed Rett syndrome diagnosis with MECP2 pathogenic variant
  • Prescription from physician specializing in Rett syndrome treatment
  • Weight-based dosing per FDA guidelines

Important distribution note: Daybue cannot be filled through CVS Specialty Pharmacy. The medication is exclusively distributed through AnovoRx via the Acadia Connect program. Contact Acadia Connect at 1-844-737-2223 for enrollment.

Submission Process

  1. Complete current Aetna PA form (download from Aetna provider portal)
  2. Gather required documentation (see checklist below)
  3. Submit via Aetna provider portal or verify current fax number
  4. Follow up within 5 business days if no acknowledgment received

Standard timeline: 30-45 days for determination; expedited appeals decided within 72 hours for urgent cases.

Clean Request Anatomy: What to Submit

Required Documentation Package

Essential documents for PA submission:

  • Completed Aetna PA form (current version)
  • MECP2 genetic test results showing pathogenic mutation
  • Specialist consultation notes confirming Rett syndrome diagnosis
  • Baseline severity assessment scores (RSBQ, CGI-I, or Clinical Severity Scale)
  • Current medication list and medical history
  • Weight-based dosing calculation per FDA guidelines
  • Medical records documenting clinical manifestations

Medical Necessity Letter Components

When drafting the medical necessity letter, include:

  • Patient history: Age of regression onset, developmental milestones lost
  • Clinical presentation: Current symptoms, functional limitations
  • Genetic confirmation: MECP2 mutation details and laboratory report
  • Treatment rationale: Daybue as first FDA-approved Rett syndrome therapy
  • Dosing justification: Weight-based calculation with safety monitoring plan

Common Denial Reasons and Solutions

Denial Reason Solution Required Documentation
Diagnosis not substantiated Submit genetic testing MECP2 pathogenic variant confirmation
Age outside label Verify patient ≥2 years Birth certificate or medical records
Missing specialist attestation Neurologist consultation Notes from Rett syndrome specialist
Quantity limits exceeded Recalculate dosing Weight-based dosing table with current weight
Non-formulary status Request formulary exception Medical necessity letter citing FDA approval

Counterforce Health Support

Counterforce Health helps patients and clinicians navigate complex prior authorization denials by analyzing denial letters and crafting evidence-backed appeals. Their platform identifies specific denial reasons and generates targeted rebuttals aligned with payer policies, significantly improving approval rates for specialty medications like Daybue.

Washington Appeals Process and External Review

Internal Appeals with Aetna CVS Health

If your initial PA is denied, Washington residents have strong appeal rights:

Step 1: Internal Appeal

  • Timeline: Submit within 180 days of denial
  • Method: Aetna provider portal or mail to appeals address
  • Decision: 60 days for standard; 72 hours for expedited
  • Required: Appeal form, denial letter, additional medical evidence

Step 2: Second-Level Internal Appeal (if available)

  • Same timeline and submission requirements
  • Final internal decision before external review

External Review Through IRO

Washington state requires insurers to offer external review through Independent Review Organizations (IROs) after internal appeals are exhausted.

Eligibility requirements:

  • Prior internal appeal denial from Aetna
  • Request filed within 4 months of final internal denial
  • Denial based on medical necessity or experimental treatment determination

Process steps:

  1. Request external review in writing to Aetna
  2. Aetna forwards to Washington OIC within 5 business days
  3. OIC assigns certified IRO from state registry
  4. IRO decision issued within 45 days (72 hours if expedited)
  5. Binding decision on Aetna if overturned

Contact information:

  • Washington Office of the Insurance Commissioner
  • Phone: 1-800-562-6900
  • Email: [email protected]
  • Address: 5000 Capitol Blvd SE, Tumwater, WA 98501
From our advocates: "We've seen several Daybue appeals succeed when families included updated MECP2 genetic reports alongside functional assessment scores showing regression. The combination of genetic confirmation and measurable clinical decline creates a compelling case for medical necessity that IROs often approve."

Coding Verification and Pre-Submission Checklist

Pre-Submission Audit

Before submitting your PA, verify:

Patient eligibility:

  • Age ≥2 years documented
  • Current Aetna CVS Health coverage confirmed
  • No pending plan changes or terminations

Clinical documentation:

  • F84.2 diagnosis code with supporting clinical notes
  • MECP2 genetic test results included
  • Specialist consultation from neurologist
  • Baseline severity assessments completed

Coding accuracy:

  • HCPCS J8499 for billing
  • Correct NDC 63090-660-01
  • Weight-based dosing calculation verified
  • Monthly quantity limits within Aetna parameters (≤3,600 mL/30 days)

Submission completeness:

  • Current Aetna PA form completed
  • All required attachments included
  • Submission method confirmed (portal vs. fax)
  • Follow-up plan established

Verification Resources

Cross-check codes with:

Quality assurance: Contact Counterforce Health for pre-submission review if you've experienced previous denials or need assistance with complex appeal documentation.

FAQ

Q: How long does Aetna CVS Health PA take in Washington? A: Standard prior authorization decisions are made within 30-45 days. Expedited appeals for urgent cases are decided within 72 hours.

Q: What if Daybue is non-formulary on my plan? A: Request a formulary exception by submitting medical necessity documentation showing Daybue as the only FDA-approved therapy for Rett syndrome.

Q: Can I request an expedited appeal? A: Yes, if delay in treatment could seriously jeopardize your health. Submit expedited appeal request with supporting clinical documentation.

Q: Does step therapy apply to Daybue? A: Typically no, since Daybue is the first and only FDA-approved therapy specifically for Rett syndrome. However, verify with your specific plan.

Q: What happens if my external review is denied? A: IRO decisions are binding on Aetna, but you can contact the Washington OIC at 1-800-562-6900 for additional guidance or file complaints about the process.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and circumstances. Always consult with your healthcare provider and insurance plan for specific coverage questions. For assistance with appeals and prior authorization challenges, contact the Washington Office of the Insurance Commissioner at 1-800-562-6900.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.